Research to be published in Science on April 29, 2016 shows how cash-hungry patent trolls are squelching innovation when the American economy depends on it more than ever. What should be done?
The new study, co-authored by Professor Lauren Cohen of Harvard Business School, Professor Umit Gurun of the University of Texas at Dallas, and Dr. Scott Duke Kominers, a Junior Fellow at the Harvard University Society of Fellows, examines the sharp rise in patent litigation in the United States during the past decade, with 2015 marking one of the highest patent lawsuit counts on record.
In theory, the rise in patent litigation could reflect growth in the commercialization of technology and innovation, as lawsuits increase proportionately as more and more companies turn to intellectual property (IP) protection to safeguard their competitive advantages. In reality, however, it’s a very different story. The authors point out that the majority of recent patent litigation has been driven by “nonpracticing entities” (NPEs) – firms that generate no products but instead amass patent portfolios just for the sake of enforcing IP rights.
Cohen, Gurun, and Kominers discuss new, large-sample evidence adding to a growing literature that suggests that NPEs—in particular, large patent aggregators—on average act as “patent trolls,” suing cash-rich firms, seemingly irrespective of actual patent infringement.
Patent trolling has a negative impact on innovation activity at targeted firms. Cohen, Gurun, and Kominers estimate that after settling with NPEs (or losing to them in court), companies on average reduce their research and development (R&D) investment by more than 25 percent. These results, Cohen, Gurun, and Kominers say, indicate a need to change U.S. intellectual property policy, particularly to screen out trolling early in the litigation process.
Although since 2010 the U.S. Congress has considered more than a dozen bills aiming to reduce patent trolling, most of the proposed policy changes focus on after-the-fact punishments for bringing lawsuits that are declared to be frivolous (or “extraordinary”) after court proceedings.
For example, H.R. 9, the “Innovation Act,” which is currently on the docket, provides for mandatory fee-shifting for patent lawsuits that the courts determine are not “reasonably justified.” In reality, however, the average costs of patent litigation are large ($1 million to $4 million) and the process is drawn out. Even with the prospect of post-trial fee shifting, patent litigation targets may thus find it cost-effective and less disruptive to simply settle with NPEs, even in unfounded lawsuits. According to the authors, this is not a sufficient solution.
So what should be done? Cohen, Gurun, and Kominers say that policies should screen out trolling at or before the time of patent assertion. The authors recommend advance review procedures that would provide preliminary evaluation as to whether the plaintiff’s infringement claims are reasonable, and whether the asserted patents are of high quality. Such advance review could cripple trolling, they conclude – pre-litigation review can separate good NPEs (and, more generally, good patent lawsuits) from bad. Legitimate infringement claims will be encouraged, whereas trolling will be screened out. This would greatly benefit innovative companies and help them propel the U.S. economy to greater heights.
The Latest on: Patent Aggregators
[google_news title=”” keyword=”Patent Aggregators” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Patent Aggregators
- Codexis gets grant for engineered acyltransferase for synthesizing statin compoundson April 23, 2024 at 5:55 am
Discover how Codexis Inc's patented acyltransferases revolutionize statin synthesis. Enhanced catalytic activity and innovative methods for producing simvastatin.
- 5 Steps to Patent an Ideaon April 20, 2024 at 5:00 pm
Think you've got a million-dollar idea? You're not alone. There's always a few people out there at any moment, convinced they've got the next big app or the next popular product, while ...
- Wista Laboratories patents new MAPT aggregation inhibitorson April 17, 2024 at 5:00 pm
Wista Laboratories Ltd. has disclosed thiazole-containing compounds acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of ...
- Church & Dwight files patent for a composition and method for converting oleuropein to hydroxytyrosol using a specific bacterial strainon April 14, 2024 at 5:00 pm
The patent also claims that the bacterial strain composition can be used to reduce or prevent oxidative stress, inflammation, and platelet aggregation in subjects. This method can involve treating ...
- What are patent rights?on April 13, 2024 at 10:51 am
The patent rights refer to the exclusive rights of the use of the inventions and innovations owned by the patent applicants (units or individuals), who are granted to, within a legal term limit ...
- Roku is planning a change users won't likeon April 11, 2024 at 12:14 pm
Roku has filed a new patent that will introduce more ads to users If implemented, it would play ads on video game consoles and Apple TVs When it was established in 2002, Roku (ROKU ...
- USPTO warns patent lawyers not to pass off AI inventions as humanon April 10, 2024 at 10:54 am
April 10 (Reuters) - The U.S. Patent and Trademark Office on Wednesday told lawyers seeking patents that they must disclose any "material" part played by artificial intelligence in creating an ...
- Roku patent invents a way to show ads over anything you plug into your TVon April 5, 2024 at 7:47 am
A patent application from the company spotted by Lowpass describes a system for displaying ads over any device connected over HDMI, a list that could include cable boxes, game consoles ...
- Fintech Playbook: Maximizing Value Through Patents And Partnershipson April 5, 2024 at 7:29 am
Patents stand at the forefront of fintech innovation ... another leader in financial data aggregation, allying with "Company X," a burgeoning fintech startup specializing in AI-driven financial ...
- Lexaria Awarded New Patentson April 2, 2024 at 2:00 am
Lexaria receives new patents in the fields of epilepsy and anti-viral agents KELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or ...
via Bing News